Clinical Trial MOTION
| Title of Trial Investigational medication in early Idiopathic Parkinson's Disease (IPD), as Add-on to single dopamine agonist (MOTION). What is Parkinson’s disease? Parkinson's is a disorder of the brain. Movement is controlled by dopamine, a chemical that carries signals between nerves in the brain. When cells that produce dopamine die or are damaged, Parkinson’s symptoms appear. Parkinson’s is a complex condition causing motor symptoms, such as shaking, muscle stiffness, slowness of movement and impaired balance. Non-motor symptoms such as constipation, sleep disturbance, fatigue, depression and cognitive changes also occur. Current treatment neither cures Parkinson’s nor stops it from advancing. See Parkinson Society Canada’s Information Sheet on Progression of Parkinson’s Disease (PDF) Parkinson’s treatment Since Parkinson’s is a progressive condition, symptoms will worsen over time and new ones may appear. Medications will need to be adjusted; perhaps taking them more frequently or at higher doses or a combination of drugs may be required to control symptoms. See Parkinson Society Canada’s Information Sheet on Parkinson’s Medications: What you need to know! (PDF) What is being investigated? The investigational medication is an inhibitor of MAO-B (Monoamine-Oxidase-B). MAO-B compounds enhance the effect of dopamine by preventing its breakdown. The investigational medication is being studied as a phase III trial to evaluate its effectiveness and safety as add-on therapy to a stable dose of a single dopamine agonist. The study will measure the change in motor symptoms, using the Unified Parkinson’s Disease Rating Scale. What kind of study is this? This study is randomised, meaning that participants will be randomly assigned to receive either the investigational active drug or an inactive drug (placebo); and double blinded, meaning that neither participants nor researchers will know the treatment being received. The objective of this study is to assess the effectiveness and safety of two doses of the investigational medication: 50 and 100 mg/day. Who can participate? The study is looking for men and women between the ages of 30 to 80 years with a confirmed diagnosis of Parkinson’s of less than 5 years. Participants should also be receiving treatment for their Parkinson’s symptoms with a single dopamine agonist. Prior to the screening visit, the person should be at a stable dose for at least 4 weeks. What is required of the participants? After randomization (treatment allocation), participants will undergo 24 weeks of treatment, with periodic visits to the doctor in-between. How large is the study? The study intends to enrol 666 participants throughout all the participating countries. In Canada, the study will enrol 40 participants. Have ethical standards been met? This study has been approved by all the Ethics Committees of the participating sites and by Health Canada. Where are the sites in Canada? The following chart indicates the Canadian locations, and contact information.
For further information, please contact the sites directly. Contents of this document are for information purposes only and do not represent advice, endorsement or recommendation for any product, service, enterprise, claims or properties by Parkinson Society Canada. ©2009 Parkinson Society Canada |
